What is the role of linker design in improving antibody–drug conjugate (ADC) performance?
This article explains how a polar sulfamide spacer (HydraSpace®) significantly enhances ADC manufacturability, stability, and therapeutic index. While ADC development has traditionally focused on target selection, antibodies, and cytotoxic payloads, this work demonstrates that linker and spacer technology is a critical determinant of ADC quality and clinical potential.
Drawing on head-to-head comparisons with marketed ADCs, the article shows how HydraSpace® enables more efficient conjugation, improved pharmacokinetics, and a better balance between efficacy and safety. The data span multiple ADC formats, including site-specific DAR4 constructs, highlighting how advanced spacer design supports more robust and scalable ADC manufacturing.
Download the article to learn how polar sulfamide spacer technology can help design next-generation antibody–drug conjugates with an enhanced therapeutic index.
